Increasing Precision in Adjuvant Therapy for Breast Cancer
Menée auprès de 6 693 patientes atteintes d'un cancer du sein de stade précoce, cette étude de phase III évalue, du point de vue du risque de récidive, de la survie sans métastases distantes et de la survie à 5 ans, la valeur prédictive d'une signature basée sur l'expression de 70 gènes pour définir l'intérêt d'une chimiothérapie
Genomic testing of tumors can enable improved matching of individual patients or groups with treatments, but it can also identify situations where a specific intervention is not effective. In the recently reported results of the Trial Assigning Individualized Options for Treatment (TAILORx), investigators showed how one assay — the 21-gene recurrence score — could select a cohort of patients who had a 99% chance of 5-year survival without distant metastasis in whom currently available cytotoxic adjuvant chemotherapy could not be justified.1 A similar result was also seen in the West German Study Group PlanB trial.2 As we consider the practical . . .
New England Journal of Medicine , éditorial, 2015